register

News & Trends - Pharmaceuticals

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced intriguing insights into how the pharma industry workforce and workplace should transform in the next 10-15 years to align with the evolving healthcare ecosystem.

“We have to really reimagine ourselves and remove the obstacles which are essentially the old structures. How do we build organisations around the needs of our customers and patients? How do we co-create meaningful, innovative solutions which add value?” Saxena questioned.

Reflecting on his extensive experience in the Asia-Pacific region, Saxena highlighted the macro dynamics shaping the pharmaceutical industry’s operational landscape.

“Access to healthcare is a universal concern. How do we build our organisations to be fit for purpose and lead the organisation into the change rather than react to it? We have start-ups who have done extremely well…,” he highlighted.

He emphasised the profound impact of the pandemic on leadership dynamics, noting how it catalysed significant shifts in people management, crucial for shaping future workforce strategies and workplace environments.

“The key value is operating in an environment which is chaotic, complex, and you don’t have a plan. Yet, you have to lead an organisation and build trust among teams,” Saxena stated.

Addressing global trends, Saxena discussed the industry’s response to workforce reductions, showcasing innovative approaches adopted by companies like Bayer to enhance internal frameworks and drive agility. While “the unlearning component is one of the biggest challenges”, these transformations are pivotal in delivering positive outcomes for both patients and investors alike.

Looking forward, Saxena outlined key actions necessary in the short-term to propel the workforce and workplaces towards his envisioned future.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Department of Health review reveals mixed results on minimum stockholding policy

Department of Health review reveals mixed results on minimum stockholding policy

Health Industry Hub | August 29, 2024 |

Pharma News: The Department of Health has concluded a 12-month review of the Minimum Stockholding Requirements (MSR) policy, assessing its […]

More


News & Trends - Pharmaceuticals

AstraZeneca-Daiichi Sankyo targeted therapy listed on the PBS in advanced breast cancer

AstraZeneca-Daiichi Sankyo targeted therapy listed on the PBS in advanced breast cancer

Health Industry Hub | August 29, 2024 |

Pharma News: Breast cancer, the second most diagnosed cancer in Australia and the leading cancer among women, affects around 58 […]

More


News & Trends - Pharmaceuticals

Leadership homecoming at Organon ANZ: New country head returns to steer future growth

Leadership homecoming at Organon ANZ: New country head returns to steer future growth

Health Industry Hub | August 29, 2024 |

Pharma News: Organon has announced the appointment of Bilal Somra as the new Country Lead for Australia and New Zealand […]

More


News & Trends - Pharmaceuticals

Sandoz secures regulatory approval for first biosimilar to Amgen's Prolia

Sandoz secures regulatory approval for first biosimilar to Amgen’s Prolia and Xgeva

Health Industry Hub | August 28, 2024 |

Pharma News: Sandoz ANZ has secured regulatory approval for its denosumab biosimilars, Jubbonti and Wyost, for the treatment of osteoporosis […]

More


This content is copyright protected. Please subscribe to gain access.